Dec 2020 $69 M No. 7 $50 to $250 million 13
3-V Biosciences, Inc.: Raise no. 7, Dec 2020 × Investors in this round 13 investors had bought by the notice of Jan 5, 2021: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $69 M of $80 M offered; $11 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dennis Hom · Executive Officer George Kemble · Executive Officer, Director Beth Seidenberg · Director Gordon Ringold · Director James Young · Director Jason Fuller · Director Jinzi Jason Wu · Director Merdad Parsey · Director Richard Rodgers · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Dennis Hom, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 5, 2021. Read the notice at the SEC .
equity SEC Feb 2019 $35 M No. 6 $10 to $50 million 19
3-V Biosciences, Inc.: Raise no. 6, Feb 2019 × Investors in this round 19 investors had bought by the notice of Feb 25, 2019: 19 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $35 M of $42 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dennis Jason Hom · Executive Officer George Kemble · Executive Officer, Director Beth Seidenberg · Director David Mott · Director Gordon Ringold · Director James Young · Director Jason Fuller · Director Jinzi Jason Wu · Director Merdad Parsey · Director Richard Rodgers · Director Xufang Jason Duan · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The total amount sold includes $20,224,082.12 in principal and interest from convertible promissory notes that was converted to Series E Preferred Stock.”On the use of proceeds: “General corporate purposes.”Signed by George Kemble, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 25, 2019. Read the notice at the SEC .
equity SEC Jun 2016 $5 M No. 5 $2 to $10 million 7
3-V Biosciences, Inc.: Raise no. 5, Jun 2016 × Investors in this round 7 investors had bought by the notice of Jul 5, 2016: 7 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $12 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice George Kemble · Executive Officer, Director Beth Seidenberg · Director David Mott · Director Gordon Ringold · Director James Young · Director Jason Fuller · Director Merdad Parsey · Director Richard Rodgers · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by George Kemble, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 5, 2016. Read the notice at the SEC .
equity, debt SEC Oct 2014 $14 M No. 4 $10 to $50 million 12
3-V Biosciences, Inc.: Raise no. 4, Oct 2014 × Investors in this round 12 investors had bought by the notice of Mar 17, 2015: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $14 M of $35 M offered; $21 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Merdad Parsey · Executive Officer, Director Rekha Hemrajani · Executive Officer Beth Seidenberg · Director David Mott · Director Gordon Ringold · Director James Young · Director Richard Rodgers · Director Robert Garland · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Merdad Parsey, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 17, 2015. Read the notice at the SEC .
equity SEC Jun 2013 $8 M No. 3 $2 to $10 million 2
3-V Biosciences, Inc.: Raise no. 3, Jun 2013 × Investors in this round 2 investors had bought by the notice of Jun 27, 2013: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $20 M offered; $13 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Merdad Parsey · Executive Officer, Director Ari Helenius · Director Beth Seidenberg · Director David Mott · Director Gordon Ringold · Director James Young · Director Robert Garland · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The total offering amount includes the purchase price of the Series C Preferred Stock, the purchase price of the Common Stock Warrants and the potential proceeds from the exercise of the Common Stock Warrants.”On the use of proceeds: “The proceeds will be used for working capital.”Signed by Merdad Parsey, MD, Ph.D, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 27, 2013. Read the notice at the SEC .
equity, options SEC Nov 2011 $20 M No. 2 $10 to $50 million 3
3-V Biosciences, Inc.: Raise no. 2, Nov 2011 × Investors in this round 3 investors had bought by the notice of Dec 20, 2012: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $20 M of $25 M offered; $5 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Merdad Parsey · Executive Officer, Director Ari Helenius · Director Beth Seidenberg · Director David Mott · Director Gordon Ringold · Director James Young · Director Robert Garland · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The amount sold includes the purchase price of the warrants and the stock.”On the use of proceeds: “The proceeds will be used for working capital.”Signed by Merdad Parsey, MD, Ph.D, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 20, 2012. Read the notice at the SEC .
equity, options SEC Jul 2009 $15 M No. 1 $10 to $50 million 4
3-V Biosciences, Inc.: Raise no. 1, Jul 2009 × Investors in this round 4 investors had bought by the notice of Jul 22, 2009: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for 3-V Biosciences, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $15 M of $30 M offered; $15 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John Curnutte · Executive Officer, Director Rick Klausner · Executive Officer, Director Ari Helenius · Director Beth Seidenberg · Director David Mott · Director Gordon Ringold · Director Robert Garland · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “The proceeds shall be used for working capital.”Signed by Glen Sato, Secretary. Source: SEC Form D, newest notice filed Jul 22, 2009. Read the notice at the SEC .
equity SEC